1,294 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
BMY Bristol-Myers Squibb Company $61.3 $100.03B Buy
Article Searches
Starboard gauges support for BMY-CELG deal https://seekingalpha.com/news/3434173-starboard-gauges-support-bmy-celg-deal?source=feed_news_all Feb 17, 2019 - Activist hedge fund Starboard Value has asked a proxy solicitor to probe the level of support among Bristol-Myers Squibb (NYSE:BMY) shareholders for its $74B deal to buy Celgene (NASDAQ:CELG), Reuters
Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B http://www.zacks.com/stock/news/354868/johnson-johnson-jnj-to-acquire-auris-health-for-%2434b?cid=CS-ZC-FT-354868 Feb 14, 2019 - Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash.
5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings http://www.zacks.com/stock/news/354851/5-drug-biotech-stocks-set-to-beat-estimates-in-q4-earnings?cid=CS-ZC-FT-354851 Feb 14, 2019 - Let us take a look at five favorable stocks, poised to beat estimates this earnings season.
BMY vs. AZN: Which Stock Is the Better Value Option? http://www.zacks.com/stock/news/354650/bmy-vs-azn-which-stock-is-the-better-value-option?cid=CS-ZC-FT-354650 Feb 14, 2019 - BMY vs. AZN: Which Stock Is the Better Value Option?
AstraZeneca's (AZN) Q4 Earnings Beat, New Drugs Drive Sales http://www.zacks.com/stock/news/354603/astrazenecas-azn-q4-earnings-beat-new-drugs-drive-sales?cid=CS-ZC-FT-354603 Feb 14, 2019 - AstraZeneca (AZN) beats earnings and sales estimates in the fourth quarter and provides encouraging outlook for 2019. Shares up.
Exelixis (EXEL) Earnings, Revenues Beat Estimates in Q4 http://www.zacks.com/stock/news/354369/exelixis-exel-earnings-revenues-beat-estimates-in-q4?cid=CS-ZC-FT-354369 Feb 13, 2019 - Exelixis's (EXEL) earnings and revenues beat expectations in the fourth quarter on strong sales of Cabometyx.
Bristol-Myers' Sprycel Gets European Nod for Label Expansion http://www.zacks.com/stock/news/354050/bristol-myers-sprycel-gets-european-nod-for-label-expansion?cid=CS-ZC-FT-354050 Feb 12, 2019 - Bristol-Myers' (BMY) oncology drug, Sprycel in combination with chemotherapy gets EC approval to treat pediatric patients with newly diagnosed Ph+ ALL.
Seattle Genetics' Adcetris Gets EC Nod for Label Expansion http://www.zacks.com/stock/news/354019/seattle-genetics-adcetris-gets-ec-nod-for-label-expansion?cid=CS-ZC-FT-354019 Feb 12, 2019 - Seattle Genetics' (SGEN) partner, Takeda Pharmaceutical receives EC approval for Adcetris in combination with AVD to treat adults with previously untreated CD30+ stage IV cHL.
Pfizer sBLA for Kidney Cancer Drug Combo Gets Priority Review http://www.zacks.com/stock/news/353912/pfizer-sbla-for-kidney-cancer-drug-combo-gets-priority-review?cid=CS-ZC-FT-353912 Feb 12, 2019 - Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets priority review in the United States. The decision is expected in June.
AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma http://www.zacks.com/stock/news/353842/abbvie-buys-rights-to-novel-immunotherapy-for-multiple-myeloma?cid=CS-ZC-FT-353842 Feb 12, 2019 - AbbVie (ABBV) enters a global strategic transaction agreement with privately-held Teneobio to develop and commercialize the latter's pre-clinical immunotherapy candidate, TNB-383B, as a multiple myeloma treatment.

Pages: 123456...130

Page 1>

Related Companies

Name Exchange Price Mkt Cap
GSK GlaxoSmithKline PLC NYSE $39.21 $97.25B
AZN Astrazeneca PLC NYSE $37.56 $95.16B
SNY Sanofi NYSE $43.75 $109.14B
LLY Eli Lilly and Company NYSE $105.71 $113.53B
NVO Novo Nordisk A/S NYSE $47.64 $114.84B
Sector: Health Care > Industry: Major Pharmaceuticals
DeepLinks for Bristol-Myers Squibb Company
BMY - Google Finance https://www.google.com/finance?q=BMY Industry related info and international coverage Summary News
BMY - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=BMY Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options